Wells Fargo
CUE icon

Wells Fargo’s Cue Biopharma CUE Stock Holding History

Wells Fargo’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$589 Hold
85
– – ﹤0.01% 6380
2025
Q4 		$783 Sell
85
-568
-87% -$10.4K ﹤0.01% 6301
2025
Q3 		$14.1K Hold
653
– – ﹤0.01% 5879
2025
Q2 		$13.4K Sell
653
-16
-2% -$341 ﹤0.01% 5881
2025
Q1 		$18.3K Hold
669
– – ﹤0.01% 5737
2024
Q4 		$21.9K Hold
669
– – ﹤0.01% 5742
2024
Q3 		$15.2K Sell
669
-20
-3% -$433 ﹤0.01% 5704
2024
Q2 		$25.6K Sell
689
-341
-33% -$16.9K ﹤0.01% 5517
2024
Q1 		$58.4K Buy
1,030
+49
+5% +$3.46K ﹤0.01% 5189
2023
Q4 		$77.7K Sell
981
-1,625
-62% -$116K ﹤0.01% 5061
2023
Q3 		$180K Buy
2,606
+287
+12% +$28K ﹤0.01% 4431
2023
Q2 		$254K Buy
2,319
+608
+36% +$71.4K ﹤0.01% 4432
2023
Q1 		$183K Buy
1,711
+107
+7% +$10.2K ﹤0.01% 4486
2022
Q4 		$137K Buy
1,604
+937
+140% +$85.7K ﹤0.01% 4379
2022
Q3 		$45K Buy
667
+1
+0.2% +$86 ﹤0.01% 5007
2022
Q2 		$50K Buy
666
+376
+130% +$44K ﹤0.01% 5012
2022
Q1 		$43K Sell
290
-298
-51% -$63.2K ﹤0.01% 5725
2021
Q4 		$200K Buy
588
+555
+1,682% +$215K ﹤0.01% 5266
2021
Q3 		$15K Hold
33
– – ﹤0.01% 6059
2021
Q2 		$12K Sell
33
-212
-87% -$82.2K ﹤0.01% 6078
2021
Q1 		$89K Sell
245
-1,509
-86% -$621K ﹤0.01% 5532
2020
Q4 		$658K Sell
1,754
-5
-0.3% -$2K ﹤0.01% 4326
2020
Q3 		$795K Sell
1,759
-100
-5% -$57.6K ﹤0.01% 4030
2020
Q2 		$1.37M Buy
1,859
+597
+47% +$432K ﹤0.01% 3569
2020
Q1 		$537K Buy
1,262
+220
+21% +$107K ﹤0.01% 3982
2019
Q4 		$496K Buy
1,042
+144
+16% +$45.2K ﹤0.01% 4375
2019
Q3 		$227K Sell
898
-7
-0.8% -$1.68K ﹤0.01% 4884
2019
Q2 		$244K Sell
905
-240
-21% -$59.7K ﹤0.01% 4855
2019
Q1 		$266K Sell
1,145
-69
-6% -$13.1K ﹤0.01% 4677
2018
Q4 		$171K Buy
1,214
+550
+83% +$99.8K ﹤0.01% 5016
2018
Q3 		$181K Buy
664
+14
+2% +$4.04K ﹤0.01% 5058
2018
Q2 		$231K Buy
650
+480
+282% +$191K ﹤0.01% 4954
2018
Q1 		$72K Buy
+170
New +$77.5K ﹤0.01% 5436

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Wells Fargo's CUE Position: Q1 2026 in Review

Wells Fargo held its Cue Biopharma (CUE) position steady in Q1 2026 at 85 shares worth $589. The position accounts for ﹤0.01% of the portfolio, ranked #6380.

Wells Fargo first reported a position in CUE in Q1 2018 and has held it in 33 quarters since. The position peaked at $1.37M in Q2 2020. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Wells Fargo held 85 shares of Cue Biopharma worth $589 as of Q1 2026.
  • Wells Fargo left its Cue Biopharma share count unchanged in Q1 2026.
  • Cue Biopharma made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6380 holding.
  • Wells Fargo first reported a position in Cue Biopharma in Q1 2018 and has held it in 33 quarters since.
  • Wells Fargo's Cue Biopharma position peaked at $1.37M in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.